PASG — Passage Bio, Inc.

Passage Bio (PASG) Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash Position: As of December 31, 2022, cash equivalents and marketable securities totaled $189.6 million, down from $315.8 million a year earlier.
• Expenses:
  • R&D expenses were $17.7 million for Q4 2022 and $86.1 million for the full year, a decrease from $33 million and $117.7 million in Q4 and full year 2021, respectively.
  • G&A expenses were $10.6 million for Q4 2022 and $49.3 million for the full year, compared to $17.2 million and $60.1 million in the previous year.
• Net Loss: The net loss was $27.1 million for Q4 and $136.1 million for the full year, improved from $51.2 million and $185.4 million in 2021.

2. Strategic Updates and Business Highlights:

• Clinical Programs:
  • PBGM01 for GM1 Gangliosidosis: Positive interim data from the Imagine-1 trial was shared, indicating a favorable safety profile and biological effects in treated patients. Plans to escalate dosing and revise inclusion criteria to enhance patient outcomes were announced.
  • upliFT-D for Frontotemporal Dementia (FTD): The company is focused on patient recruitment and expects to report initial safety and biomarker data from Cohort 1 in the second half of 2023.
• Research Initiatives: Continued advancement of preclinical programs in ALS, Huntington's disease, and temporal lobe epilepsy, alongside a commitment to explore strategic alternatives for other clinical-stage programs.

3. Forward Guidance and Outlook:

• The company anticipates existing cash resources will fund operations into the first half of 2025.
• Key milestones for 2023 include reporting initial safety and biomarker data from Cohort 4 of the GM1 study by mid-year and dosing the first patient at a higher dose in the second half of 2023.

4. Bad News, Challenges, or Points of Concern:

• Cash Burn: Despite a reduced cash burn rate, the significant drop in cash reserves year-over-year raises concerns about long-term sustainability without additional funding.
• Regulatory Uncertainty: Changes to study inclusion criteria and the need for regulatory review may delay pivotal study discussions and timelines.
• Patient Recruitment: While there is interest in trials, the ability to meet revised inclusion criteria and recruit patients effectively remains a challenge.

5. Notable Q&A Insights:

• Dose Escalation: The company confirmed plans to escalate dosing for PBGM01, independent of Cohort 4 results, and will treat both early and late infantile patients.
• Clinical Outcomes: The focus will be on achieving durable decreases in GM1 ganglioside levels and improvements in developmental metrics as key outputs for potential registrational studies.
• Biomarker Targets: For PBFT02, initial data will focus on CSF progranulin levels, with expectations to reach physiological levels based on preclinical data.
• Patient Enrollment: The company is confident in its ability to recruit patients under the revised criteria, with ongoing discussions with regulatory authorities to define endpoints for future studies.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A session, providing a balanced view of Passage Bio's current standing and future outlook.